Literature DB >> 18004604

Octacosanol administration to humans decreases neutral sterol and bile acid concentration in feces.

Sylvia Keller1, Franziska Gimmler, Gerhard Jahreis.   

Abstract

To investigate octacosanol (OC) metabolism in humans and its influence on cholesterol metabolism, two studies were conducted. In the first study ten healthy women received daily 30 mg OC for a period of 4 weeks. Blood and feces samples were collected at baseline and after the intervention. Serum concentrations of total cholesterol, LDL cholesterol, and HDL cholesterol were not altered following OC administration. Concentrations of excreted cholesterol end products decreased with the intervention (neutral sterols: 24.6 +/- 9.7 mg/g vs. 20.3 +/- 7.5 mg/g dry matter, P < 0.05; bile acids: 6.47 +/- 3.89 mg/g vs. 4.03 +/- 2.26 mg/g dry matter, P < 0.05). OC was not detected in serum samples, but the fecal OC concentration increased after the intervention period (11 +/- 7 microg/g vs. 817 +/- 179 microg/g dry matter, P < 0.05). In the second kinetic study on three participants, OC was identified in serums after oral application of 50 mg OC within 8 h. The decrease in the concentration of fecal cholesterol end products may underline a systemic effect of OC on cholesterol metabolism, even though the serum cholesterol levels were not influenced.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18004604     DOI: 10.1007/s11745-007-3127-4

Source DB:  PubMed          Journal:  Lipids        ISSN: 0024-4201            Impact factor:   1.880


  33 in total

1.  Comparative study of the efficacy and tolerability of policosanol and lovastatin in patients with hypercholesterolemia and noninsulin dependent diabetes mellitus.

Authors:  N Crespo; J Illnait; R Más; L Fernández; J Fernández; G Castaño
Journal:  Int J Clin Pharmacol Res       Date:  1999

2.  Policosanol inhibits cholesterol biosynthesis and enhances low density lipoprotein processing in cultured human fibroblasts.

Authors:  R Menendez; S I Fernandez; A Del Rio; R M Gonzalez; V Fraga; A M Amor; R M Mas
Journal:  Biol Res       Date:  1994       Impact factor: 5.612

3.  Two patterns of neutral steroid conversion in the feces of normal North Americans.

Authors:  T D Wilkins; A S Hackman
Journal:  Cancer Res       Date:  1974-09       Impact factor: 12.701

4.  Inhibition of cholesterol biosynthesis in cultured fibroblasts by D003, a mixture of very long chain saturated fatty acids.

Authors:  R Menéndez; R Más; A M Amor; I Rodeiros; R M Gonzalez; J L Alfonso
Journal:  Pharmacol Res       Date:  2001-10       Impact factor: 7.658

5.  Assessment of the effects of D-003, a new antiplatelet and lipid-lowering compound, in healthy volunteers. A phase I clinical study.

Authors:  Gladys Castaño; Rosa Más; Lilia Fernández; Ernesto López; Juan A Gutiérrez; José Illnait; Julio C Fernández; Rafael Gámez; Estrella Alvarez
Journal:  Drugs R D       Date:  2002

6.  Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial.

Authors:  Heiner K Berthold; Susanne Unverdorben; Ralf Degenhardt; Michael Bulitta; Ioanna Gouni-Berthold
Journal:  JAMA       Date:  2006-05-17       Impact factor: 56.272

Review 7.  Policosanol: clinical pharmacology and therapeutic significance of a new lipid-lowering agent.

Authors:  Ioanna Gouni-Berthold; Heiner K Berthold
Journal:  Am Heart J       Date:  2002-02       Impact factor: 4.749

8.  Policosanol modulates HMG-CoA reductase activity in cultured fibroblasts.

Authors:  R Menéndez; A M Amor; I Rodeiro; R M González; P C González; J L Alfonso; R Más
Journal:  Arch Med Res       Date:  2001 Jan-Feb       Impact factor: 2.235

9.  Effects of a policosanol supplement on serum lipid concentrations in hypercholesterolaemic and heterozygous familial hypercholesterolaemic subjects.

Authors:  A Greyling; C De Witt; W Oosthuizen; J C Jerling
Journal:  Br J Nutr       Date:  2006-05       Impact factor: 3.718

10.  Oral administration of D-003, a mixture of very long chain fatty acids prevents casein-induced endogenous hypercholesterolemia in rabbits.

Authors:  R Menéndez; R Más; J Pérez; R M González; S Jiménez
Journal:  Can J Physiol Pharmacol       Date:  2004-01       Impact factor: 2.273

View more
  5 in total

1.  Activation of AMP-kinase by policosanol requires peroxisomal metabolism.

Authors:  Subhashis Banerjee; Sarbani Ghoshal; Todd D Porter
Journal:  Lipids       Date:  2011-02-27       Impact factor: 1.880

2.  Octacosanol enhances the proliferation and migration of human umbilical vein endothelial cells via activation of the PI3K/Akt and MAPK/Erk pathways.

Authors:  Yu-Wei Liu; Pei-Yuan Zuo; Xiang-Nan Zha; Xing-Lin Chen; Rong Zhang; Xiao-Xiao He; Cheng-Yun Liu
Journal:  Lipids       Date:  2015-02-01       Impact factor: 1.880

3.  Regulation of HMGCoA reductase activity by policosanol and octacosadienol, a new synthetic analogue of octacosanol.

Authors:  Simonetta Oliaro-Bosso; Emanuela Calcio Gaudino; Stefano Mantegna; Enrico Giraudo; Claudia Meda; Franca Viola; Giancarlo Cravotto
Journal:  Lipids       Date:  2009-09-11       Impact factor: 1.880

4.  Octacosanol restores stress-affected sleep in mice by alleviating stress.

Authors:  Mahesh K Kaushik; Kosuke Aritake; Atsuko Takeuchi; Masashi Yanagisawa; Yoshihiro Urade
Journal:  Sci Rep       Date:  2017-08-21       Impact factor: 4.379

5.  Octacosanol and policosanol prevent high-fat diet-induced obesity and metabolic disorders by activating brown adipose tissue and improving liver metabolism.

Authors:  Rahul Sharma; Takashi Matsuzaka; Mahesh K Kaushik; Takehito Sugasawa; Hiroshi Ohno; Yunong Wang; Kaori Motomura; Takuya Shimura; Yuka Okajima; Yuhei Mizunoe; Yang Ma; Zahara M Saber; Hitoshi Iwasaki; Shigeru Yatoh; Hiroaki Suzuki; Yuichi Aita; Song-Iee Han; Yoshinori Takeuchi; Naoya Yahagi; Takafumi Miyamoto; Motohiro Sekiya; Yoshimi Nakagawa; Hitoshi Shimano
Journal:  Sci Rep       Date:  2019-03-26       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.